Saniona (SANION) Q4 2025 earnings summary

Executive summary

• Achieved a transformational year, leveraging partnerships to build a differentiated CNS pipeline and secure high-value agreements, resulting in strong financial performance and a robust proprietary pipeline advancing toward clinical trials.

• Key licensing agreements with Jazz Pharmaceuticals and Acadia generated USD 70.5 million in upfront payments and eligibility for up to USD 1.6 billion in milestones and royalties.

• Strengthened leadership and operational capabilities to support clinical execution and pipeline advancement.

Financial highlights

• Full-year revenue rose to SEK 434.4 million from SEK 334.7 million year-over-year, driven by partnership payments.

• Operating profit for the year was SEK 271.0 million, up from SEK 241.9 million; net profit reached SEK 284.6 million, up from SEK 188.7 million.

• Q4 revenue dropped to SEK 4.6 million from SEK 313.4 million, with a Q4 net loss of SEK 41.7 million compared to a profit of SEK 247.1 million in Q4 2024.

• Cash and cash equivalents at year-end were SEK 580.8 million, up from SEK 303.3 million.

• Basic EPS for the year was SEK 2.21, up from SEK 1.77.

Outlook and guidance

• Plans to advance three key internal assets (SAN2668, SAN2465, SAN2219) toward clinical trials, with two Phase 1 studies targeted for 2026 and a third in early 2027.

• Expects to progress at least one program to Phase 3 internally and others via partnerships.

• Anticipates continued revenue from ongoing research collaborations and potential regulatory approval of tesofensine in Mexico.